

BIOPHARMA

as a Strategic Asset: Insights

The U.S. system of developing medicine is unique – it relies on a mix of private sector, public sector and research institutions working together. While not perfect, a dedicated set of actions to invest in innovation has helped the U.S. biopharmaceutical industry become a true strategic asset – one that drives innovation and effectively addresses major crises, as with COVID-19.



AMERICANS VIEW A STRONG BIOPHARMACEUTICAL INDUSTRY AS A VITAL STRATEGIC ASSET, ESSENTIAL FOR PROTECTING US AGAINST FUTURE PANDEMICS.

- 86% of voters believe it is important for the country to have a strong biopharmaceutical industry.ⁱ
- Americans don't want to cede biopharmaceutical leadership to other nations – 82% of voters think that a strong American biopharmaceutical industry is a matter of national security.ⁱⁱ
- 88% of voters agree that now is the time to make investments to make our health care system stronger and more resilient.ⁱⁱⁱ
- 83% of voters agree scientists and researchers at America's biopharmaceutical companies are making amazing discoveries that are improving our health.^{iv}



AMERICANS KNOW THE PRIVATE SECTOR DELIVERED IN A TIME OF GLOBAL NEED – AND KNOW THE RISK OF LOSING IT.

- Americans believe companies are important for solving problems; two-thirds said companies could do a better job coordinating the vaccine rollout than the government could, for example.^v
- 84% of voters agree the coronavirus pandemic has shown the large and important role biopharmaceutical companies have in research and development for discovering new treatments, cures and vaccines.^{vi}
- And 82% of voters agree it is important the biopharmaceutical companies and vaccine makers have adequate funds to discover, develop and test new drugs.^{vii}
- Americans' fear about the vaccine rollout being too slow dropped from 47% in January to 36% in March 2021.^{viii} Among the likely contributing factors is the biopharmaceutical industry's ability to leverage advanced manufacturing capabilities that have accelerated production and distribution – demonstrating continued innovation and impact.
 - Thanks to industry collaborations, current forecasts estimate that the number of vaccines produced to date will increase by more than 600% from March to December 2021.^{ix}



AMERICANS VALUE THE BIOPHARMACEUTICAL INDUSTRY AND PUBLIC-PRIVATE COLLABORATION, NOT RADICAL CHANGE.

- 62% of Americans viewed the industry positively a year into the pandemic – a number 30 points higher than in January 2020.^x
- 79% of voters believe the coronavirus pandemic has shown how much we can accomplish when the private and public sectors work together to solve global problems, and we should use that to attack other issues like health care affordability.^{xi}
- 79% of voters think we need to be cautious about changes we make to the stressed health care system coming out of COVID-19.^{xii}

i. [Public Opinion Strategies National Survey](#), April 2021.

ii. [Center for Individual Freedom National Survey](#), May 2021.

iii. [Consumers for Quality Care 2021 Healthcare Priorities Poll](#), January 2021.

iv. [Public Opinion Strategies National Survey](#), April 2021.

v. [The Harris Poll](#), March 2021.

vi. [Public Opinion Strategies National Survey](#), April 2021.

vii. [Future Majority Health Care Poll and Strategy](#), February 2021.

viii. [The Harris Poll COVID-19 Tracker](#), March 2021.

ix. [Airfinity Global COVID-19 Vaccine Production Summit](#), March 2021.

x. [The Harris Poll](#), March 2021.

xi. [Public Opinion Strategies National Survey](#), April 2021.

xii. [Consumers for Quality Care 2021 Healthcare Priorities Poll](#), January 2021.